Clinical Trial Update: Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER [Phase 2]

View source ↗

Summary

Extension study update for mavacamten (MYK-461) in adults with symptomatic obstructive hypertrophic cardiomyopathy; the Phase 2 PIONEER extension has completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertrophic Cardiomyopathy

Drugs mentioned

• Mavacamten (mavacamten)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hypertrophic Cardiomyopathy | Phase 2 | Status: COMPLETED | Results posted: 2025-01-09